Provista Diagnostics, Inc., a Delaware company, is a privately held molecular diagnostics company offering diagnostic…
Year: 2011
EpiCept Corporation recently announced operating and financial results for the year 2010, and provided an update on its key business initiatives.
Exosome Diagnostics is a specialized bio-pharmaceutical company that develops a unique kind of genetic-based diagnostic…
FT. MYERS, Fla., Feb. 10, 2011 /PRNewswire/ — NeoGenomics, Inc. (OTC Bulletin Board: NGNM), a leading provider of cancer-focused genetic testing services, today reported its results for the fourth quarter 2010 and fiscal year ended December 31, 2010.
Cancer, a word that strikes a chord of fear in many, is a fighting word. At $47.7bn, cancer is one of the largest, fastest growing markets in the pharmaceutical industry, and while it is a match we have yet to win, researchers and scientists have on their boxing gloves and are staying in the fight.
ADVENTRX Pharmaceuticals, Inc., a specialty pharmaceutical company focused on acquiring, developing and commercializing proprietary product candidates principally for the treatment of cancer, recently provided an update on its product candidate, ANX-514, its polysorbate 80-free formulation of docetaxel.
Seno Medical is a company focused on cancer using its new patented opto-acoustic technology. This…
T-Ray Science, Inc., a medical device company committed to commercializing innovative systems for the early detection of cancer announces that shareholders approved a change of the name of the Company to Verisante Technology, Inc.